The same event can reach both: a study opening is one line under its program in the brief, and one study’s change in the alerts.
The registry lists 2,977 studies for Osteoarthritis across more than 10 countries. 438 are recruiting or about to start. 1,900 of them are mainly about Osteoarthritis (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17. Counting its 2 narrower conditions too, such as Osteoarthritis, Knee: 5,989 studies, 1,043 open.
ClinicalTrials.gov finds 6,493 studies for Osteoarthritis.How that becomes 2,974 here
This page counts the studies the registry files under Osteoarthritis, and those it files under no condition that list Osteoarthritisthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 15, 2026. How condition pages count
6,493Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
−171List Osteoarthritis as a condition, but the registry did not file them under itMost often written as “Shoulder Osteoarthritis” (17), “Degenerative Osteoarthritis” (13), and “Hand Osteoarthritis” (10). The registry filed them under other conditions only, most often Joint Diseases (23) and Arthritis, Rheumatoid (22).
−340Match it another way243 name it in the title, 19 in a keyword, and 78 by a synonym or other text the search reads.
2,974The count on this page275 of them list Osteoarthritis in their own words; the registry filed them under no condition.
What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.
“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.
In phase 3
Company
Phase-3 primary completion
Meets, by arms
allogeneic human adipose-derived mesenchymal stem cells☆ Track1 live phase-3 study: NCT07106229
The 5 in phase 3 with the nearest primary completion, of 23 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.
Primary completion in the next 12 months (7)
Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.
Nov 2026 est.KBP-336· KeyBioscience AG · Phase 2named, not the main aimNCT06833749 Efficacy and Safety of KBP-336 in Obese Individuals with Osteoarthritis — primary endpoint: The proportional change in body weight from baseline to endpoint · 600 enrolled
Nov 2026 est.enekinragene inzadenovec· Pacira BioSciences, Inc. · Phase 2named, not the main aimNCT06884865 A Study to Assess Safety and Tolerability of PCRX-201 in Subjects With Painful Osteoarthritis of the Knee — primary endpoint: Incidence (number and percent) of treatment-emergent adverse events (TEAEs) for PCRX-201 Dose A and Dose B versus placebo from Week 1 through Week 52 · 135 enrolled
Feb 2027 est.Allocetra· Enlivex Therapeutics Ltd. · Phase 2main aimNCT07580716 Intra-Articular Allocetra in Patients With Primary Knee Osteoarthritis — primary endpoint: Western Ontario and McMaster Universities Arthritis Index (WOMAC) Pain score at 3 months · 182 enrolled
Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.
What is being tested here
Drugs under test in Osteoarthritis studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted
167studies finish main data collection within a year9 of them phase 3
Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.
Of the 285 Osteoarthritis studies recruiting now, 157 (55%) set no upper age limit and 71 (25%) stop at 75 or younger. 22 (8%) take children under 18. 3 (1%) are for women only and 0 (0%) for men only; 30 (11%) take healthy volunteers.
Across all 2,977 studies, recruiting or not: 26% stop at 75 or younger and 9% at 65; 7% take children; 2% are for women only and 1% for men only; 14% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.
How long Osteoarthritis studies take
Of 84 phase 3 interventional studies under Osteoarthritis, half reached primary completion within 17 months of starting, counting those still running.
Start to primary completion
Every sponsor
Industry
Non-industry
Phase 1
20 mo9–47 · 58 studies
11 mo5–26 · 35 studies
—
Phase 1/2
32 mo12–47 · 25 studies
—
—
Phase 2
19 mo10–38 · 82 studies
17 mo9–32 · 54 studies
—
Phase 3
17 mo11–27 · 84 studies
15 mo10–22 · 60 studies
—
Phase 4
28 mo11–60 · 63 studies
—
28 mo14–60 · 54 studies
Interventional, no phase
28 mo11–57 · 711 studies
38 mo15–81 · 135 studies
26 mo10–51 · 576 studies
Observational
57 mo21–141 · 228 studies
93 mo43–184 · 82 studies
36 mo12–97 · 146 studies
Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out
What changed recently
From the registry's own updates since Oct 18, 2026.